CTIS2022-502743-35-00RecruitingPhase 1
B-cell depletion for the treatment of patients with amyotrophic lateral sclerosis (ALS) - A Randomized, Double-blind, Placebo controlled Pilot Study in Patients with Amyotrophic Lateral Sclerosis for the Evaluation of Efficacy and Safety of B-Cell Depletion with Rituximab (ABCD) - RituxALS01
Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.0 sites52 target enrollmentStarted: January 27, 2023Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Enrollment
- 52
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 65+ (—)
- Sex
- All
Inclusion Criteria
- •Disease duration of sporadic ALS is = 24 months after symptom onset and symptoms have not progressed to a permanent need of assisted ventilation of any kind (including non-invasive ventilation)., Age = 18 years, Written consent to participate in the study, The patient is capable to attend study visits, Medication with riluzole at a stable dose of 50 mg BID for = 30 days prior to the screening visit and if possible, throughout the study., Slow vital capacity (VC) equal to or more than 75% of the predicted normal value for gender, height and age at the screening visit, Recommended standard vaccination according to STIKO (incl. COVID-19 vaccination). With the exception of Hepatitis B. Hepatitis B serology will be analysed at screening as to exclude an acute or underlying infection. In case of missing vaccination, it is recommended to perform the vaccination parallel to the trial (dose 1 before first infusion, dose 2 before third infusion)., Patients with the capacity to give informed consent
Exclusion Criteria
- •Dysfunction (other than ALS) that could distort or obscure the diagnosis of ALS., Patients with a serious impairment of the immune system, Severe heart failure (New York Heart Association Class IV) or severe, uncontrolled heart disease, Patients having severe disease in the renal, cardiovascular or hematological system, Patients with neutrophils < 1000 cells per µl and/or platelet counts 75.000 cells per µl, Any medical condition that, in the opinion of the Investigator, might interfere with the patient’s participation in the trial or poses any added risk for the patient, Patients with other causes of neuromuscular weakness, Patients with severe active psychiatric illness, Patients with a diagnosis of another neurodegenerative disease (e.g. Parkinson disease, Alzheimer’s disease), Participation in any other investigational drug study or exposure to an investigational drug within 5 half-lives of the study drug at baseline, Patients with a history of recurrent or chronic infections or with underlying diseases which may further predispose patients to serious infection, Patients with a tracheostomy or ongoing treatment (more than 7 consecutive days in the 4 weeks prior to the screening visit) requiring noninvasive positive pressure ventilation of any kind, Hypersensitivity to the active substance, mouse proteins or sodium citrate, polysorbate 80, Known cytokine release syndrome after infusions, Hypersensitivity to the adjuvant medication (paracetamol, methylprednisolone and dimetinden maleate), Pregnancy or lactation, The patient has used edaravone or sodium phenylbutyrate–taurursodiol in the first week before the baseline visit, Sexually active male and female patients of reproductive potential (female patients/ female partners of patients less than 12 months postmenopausal) who do not use highly effective contraception methods (pearl index <1) during and up to 12 months after treatment, Patients with HIV infections, Active severe infections (e.g. tuberculosis, sepsis and opportunistic infections), History of chronically active hepatitis including active or chronic hepatitis B, acute or chronic hepatitis C, History of a tuberculosis (TB) infection, signs/symptoms of TB or close contact with a person with an active TB infection, Clinically significant infection involving intravenous administration of antibiotics and hospitalization in the 4 weeks prior to the screening visit
Investigators
Similar Trials
Recruiting
Phase 2
B-cell depletion for the treatment of patients with amyotrophic lateral sclerosis (ALS) - A Randomized, Double-blind, Placebo controlled Pilot Study in Patients with Amyotrophic Lateral Sclerosis for the Evaluation of Efficacy and Safety of B-Cell Depletion with Rituximab (ABCD)G12.2Motor neuron diseaseDRKS00030948Deutsches Zentrum für Neurodegenerative Erkrankungen e.v.65
Not yet recruiting
Phase 2
Comparing Use of B-cell depletion therapy to Immunoglobulin in Chronic inflammatory demyelinating polyneuropathy (CUBIC) clinical trial.Chronic inflammatory demyelinating polyneuropathy (CIDP).Inflammatory and Immune System - Autoimmune diseasesNeurological - Other neurological disordersACTRN12623001336673Western Sydney Local Health District35
Not yet recruiting
Not Applicable
Clinical study on the reversal of indolent B cell lymphoma with fuzheng Huatuanjiedu decoctioInert B cell lymphomaITMCTR2000003820onghua Hospital affiliated to Shanghai University of Traditional Chinese Medicine
Not yet recruiting
Not Applicable
Study on the efficacy of rituximab in patients with polymyalgia rheumaticapolymyalgia rheumaticaNL-OMON27507one. This is an investigator initiated trial50
Active, not recruiting
Phase 4
Investigating cardiac energy levels in people with lean-type type 2 diabetesType 2 diabetes mellitusNutritional, Metabolic, EndocrineISRCTN85605342niversity of Leeds56